EMA urges recall of MS drug Zinbryta

EMA recommended immediate suspension and recall of multiple sclerosis drug Zinbryta daclizumab from Biogen Inc. (NASDAQ:BIIB) and partner AbbVie Inc. (NYSE:ABBV) following 12 worldwide reports of inflammatory brain disorders, including encephalitis and meningoencephalitis.

Read the full 331 word article

User Sign In